CMP
APLS

Coston McIsaac & Partners’s Apellis Pharmaceuticals APLS Stock Holding History

Coston McIsaac & Partners’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,000
Closed -$136K – 765
2022
Q3 		$136K Buy
+2,000
New +$118K 0.06% 127

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Coston McIsaac & Partners's APLS Position: Q4 2022 in Review

Coston McIsaac & Partners sold out of Apellis Pharmaceuticals (APLS) in Q4 2022, closing a stake of 2,000 shares — an estimated $136K sold.

Coston McIsaac & Partners first reported a position in APLS in Q3 2022 and held it in 1 quarter. The position peaked at $136K in Q3 2022. 244 funds tracked by Wall St. Rank hold APLS as of Q4 2022.

  • Coston McIsaac & Partners reported no remaining Apellis Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Coston McIsaac & Partners sold 2,000 Apellis Pharmaceuticals shares in Q4 2022, an estimated $136K.
  • Coston McIsaac & Partners first reported a position in Apellis Pharmaceuticals in Q3 2022 and held it in 1 quarter.
  • Coston McIsaac & Partners's Apellis Pharmaceuticals position peaked at $136K in Q3 2022.
  • 244 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2022.

Based on Coston McIsaac & Partners's 13F filing for Q4 2022, filed 9 Feb 2023.